^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ASKC202

    i
    Other names: ASKC202
    Associations

    News

    Trials
    Company:
    Aosaikang Pharma
    Drug class:
    c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 (clinicaltrials.gov)
    P1, N=150, Recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: May 2022 --> Aug 2022
    Enrollment open • Trial initiation date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    ASKC202
    2years
    Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Jiangsu Aosaikang Pharmaceutical Co., Ltd.
    New P1 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    ASKC202